The short version of receptor agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-30. Anything still debated is marked as such rather than presented as settled.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
=== Purity and purification === TLC helps show the purity of a sample. A pure sample should only contain one spot by TLC. TLC is also useful for small-scale purification. Because the separated compounds will be on different areas of the plate, a scientist can scrape off the stationary phase particles containing the desired compound and dissolve them into an appropriate solvent. Once all the compound dissolves in the solvent, they filter out the silica particles, then evaporate the solvent to isolate the product. Big preparative TLC plates with thick silica gel coatings can separate more than 100 mg of material. TLC is useful for larger-scale purification and isolation to quickly test solvent mixtures before running flash column chromatography on a large batch of impure material. A compound elutes from a column when the amount of solvent collected is equal to 1/RF. The eluent from flash column chromatography gets collected across several containers (for example, test tubes) called fractions. TLC helps show which fractions contain impurities and which contain pure compound. Furthermore, two-dimensional TLC can help check if a compound is stable on a particular stationary phase. This test requires two runs on a square-shaped TLC plate. The plate is rotated by 90º before the second run. If the target compound appears on the diagonal of the square, it is stable on the chosen stationary phase. Otherwise, it is decomposing on the plate. If this is the case, an alternative stationary phase may prevent this decomposition.
==== Arrest ==== Following the attack on the Dutch news outlet De Telegraaf and the murders of journalist Martin Kok and lawyer Derk Wiersum, Ridouan Taghi became the most wanted man in the Netherlands for several years, with multiple international arrest warrants in his name. He was also ranked as one of the main fugitives on the Interpol list. To anyone who was able to give information that could have led to his arrest, a reward of €100.000 was promised by the Dutch authorities, which was the highest reward for a fugitive in Dutch history. Taghi's right-hand man Saïd Razzouki took refuge in Medellín, Colombia under the protection of the Oficina de Envigado and the Clan del Golfo cartel, but was later on arrested by the Colombian authorities, and the United States' FBI and DEA.
== External links == Association of Biomolecular Resource Facilities ABRF Federation of American Societies for Experimental Biology FASEB ABRF Discussion Forum Journal of Biomolecular Techniques ABRF at LinkedIn Leadership
Sources: en.wikipedia.org
Hegseth was sworn in as the secretary of defense by JD Vance on January 25. Hegseth identified several priorities for the Department of Defense, including to "revive the warrior ethos", restore trust in the military, redevelop the nation's industrial base, ease the department's process to purchase weaponry, defend the US domestically, engage with Indo-Pacific to deter China, and support Trump's effort to "end wars responsibly"—including the Russo-Ukrainian War and the Middle Eastern crisis. In a call to Israeli prime minister Benjamin Netanyahu a day after being sworn in, Hegseth said that the United States was "fully committed" to the security of Israel. Hegseth revoked the security clearance and detail of Mark Milley, the former chairman of the Joint Chiefs of Staff and chief of staff of the Army who later became a critic of Trump, and ordered an inspector general inquiry into Milley's tenure as chairman of the Joint Chiefs of Staff; the inspector general of the Department of Defense, Robert Storch, was removed from his position when Trump dismissed several inspectors general. According to The Washington Post, the Department of Defense Education Activity began removing certain books on immigration and sexuality. Hegseth visited the Mexico–United States border with Tom Homan, Trump's border czar, in El Paso, Texas, in February, where he stated that the federal government intended to gain complete "operational control of the southern border". He renamed Fort Liberty to Fort Bragg, its original name honoring the Confederate general Braxton Bragg.
The Earl S. Richardson Library's is the main academic information resource center on the campus. Constructed in 2008, the building covers approximately 222,517 square feet. The library's holding constitutes over 500,000 volumes, and access to over 1 million e-books and 5,000 periodical titles. There are 167 online databases that are subscribed to the Library. Reading and studying spaces are provided with wired and wireless access to databases for research. One such collection in the volumes includes books on Africa, with an emphasis on sub-Saharan Africa. The African-American collection includes papers and memorabilia of such persons as Emmett Jay Scott, secretary to Booker T. Washington. The Forbush Collection is composed of materials associated with the Quakers and slavery. The Martin D. Jenkins Collection was acquired in 1980.
=== Dipeptides === The simplest peptide building blocks are dipeptides. Nanotubes formed from dipeptides are the widest among peptide nanotubes. An example of a dipeptide that has been studied is a peptide from the diphenylalanine motif of the Alzheimer's β-amyloid peptide. Dipeptides have also been shown to self-assemble into hydrogels, another form of nanostructures, when connected to the protecting group Fluorenylmethyloxycarbonyl chloride. Experiments focusing on the dipeptide Fmoc-Diphenylalanine have been conducted that have explored the mechanism in which Fmoc-diphenylalanine self-assembles into hydrogels via π-π interlocked β-sheets. Phenylalanine has an aromatic ring, a crucial part of the molecule due to its high electron-density, which favors self-assembly where the rings stack and enable the assembly to occur.
== Medical uses == Oxazepam is an intermediate-acting benzodiazepine with a slow onset of action, so it is usually prescribed to individuals who have trouble staying asleep, rather than falling asleep. It is commonly prescribed for anxiety disorders with associated tension, irritability, and agitation. It is also prescribed for drug and alcohol withdrawal, and for anxiety associated with depression. Oxazepam is sometimes prescribed off-label to treat social phobia, post-traumatic stress disorder, insomnia, premenstrual syndrome, and other conditions.
Sources: en.wikipedia.org
=== Anthropogenic arsenic compounds === Anthropogenic (man-made) sources of arsenic, like the natural sources, are mainly arsenic oxides and the associated anions. Man-made sources of arsenic, include wastes from mineral processing, swine and poultry farms. For example, many ores, especially sulfide minerals, are contaminated with arsenic, which is released in roasting (burning in air). In such processing, arsenide is converted to arsenic trioxide, which is volatile at high temperatures and is released into the atmosphere. Poultry and swine farms make heavy use of the organoarsenic compound roxarsone as an antibiotic in feed. Some wood is treated with copper arsenates as a preservative. The mechanisms by which these sources affect "downstream" living organisms remains uncertain but are probably diverse. One commonly cited pathway involves methylation. The monomethylated acid, methanearsonic acid (CH3AsO(OH)2), is a precursor to fungicides (tradename Neoasozin) in the cultivation of rice and cotton. Derivatives of phenylarsonic acid (C6H5AsO(OH)2) are used as feed additives for livestock, including 4-hydroxy-3-nitrobenzenearsonic acid (3-NHPAA or Roxarsone), ureidophenylarsonic acid, and p-arsanilic acid. These applications are controversial as they introduce soluble forms of arsenic into the environment.
== Origins == As a student in Paris between 1946 and 1960, Senegalese historian Cheikh Anta Diop wrote a series of essays charting the development of Africa. Diop's work was later seen as a blueprint for former President of South Africa Thabo Mbeki. When giving his famous "I Am an African" speech at Cape Town, celebrating the adoption of a new Constitution of South Africa, Mbeki said:
=== Sara Dhadwal === Sara Dhadwal (Priyanga Burford) is the president of Pierpoint London in series 1, and oversees its new hire program. Firm and principled, she initially clashes with Gus Sackey when he castigates her for promoting Pierpoint's cutthroat culture, which he blames for the death of his colleague Hari Dhar. However, Sara gradually becomes more in favor of culture change at the company; she views Eric as the primary embodiment of Pierpoint's toxicity, and fires him after Harper reports Eric locking her in a conference room to berate her. She also tries to become a more supportive figure to Gus, but he grows increasingly disillusioned with the firm, and purposely sabotages his interview on reduction-in-force (RIF) day. The same day, Pierpoint's global head of FICC, Bill Adler, offers Harper a chance to retract her complaint against Eric to bring him back to the firm; Sara takes her aside and tries talking her out of it, telling her she has the power to fundamentally change the culture of Pierpoint. Harper, however, rebuffs Sara for seeing her as a victim, and agrees to have Eric rehired.
In the United States, the first glass nursing bottle was patented by C.M. Windship in 1841. It was intentionally shaped like the mother's breast. In 1845 the Alexandra Feeder was marketed in England. In Paris, the "Biberon" was introduced by M. Darbo: it was reported to be quite popular in a review from 1851. As the group American Collectors of Infant Feeders notes, by "the late 1800s a large variety of glass nursing bottles were produced in the United States", and the U.S. Patent Office had issued more than 200 patents for various designs of nursing bottles by the 1940s—designed to lie flat or stand up straight, with openings on their sides or ends, with detachable or permanently attached nipples, etc.
=== Effect on metabolism === Horses with PSSM have elevated levels of muscle glycogen at rest. During exercise, glycogen levels are depleted faster than is seen in unaffected horses, and are reduced down to levels considered normal for a resting non-PSSM horse. This demonstrates that glycogen metabolism is actually normal in these animals. However, PSSM horses synthesize muscle glycogen at double the rate of a normal horse once exercise has ceased, which leads to elevated muscle glycogen. The exact mechanism of abnormal glucose metabolism has not yet been established, but it may have similarities to phosphofructokinase deficiency in humans. Quarter Horse-related breeds with PSSM show insulin sensitivity, which improves glucose uptake by cells, and these horses clear the blood of glucose more quickly after eating than unaffected horses. This provides easy access to glucose by the muscles, which can then use the substrate to produce glycogen. The GSY1 defect, which up-regulates the glycogen synthase enzyme, allows the muscles to use this glucose to rapidly produce glycogen for storage in the muscle. Surprisingly, increased insulin sensitivity is not seen in draft horse breeds. Dietary and exercise manipulation may be used to counteract these metabolic changes. Approximately 50% of horses that adhere to the dietary recommendations, and 90% of horses that adhere to both dietary and exercise recommendations, have few to no episodes of exertional rhabdomyolysis.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.